Mirum Pharmaceuticals, Inc. (MIRM) · Sep 28, 2026 · Other events

Mirum wins FOP approval and posts strong AZURE-1 HDV result

Above the bar — AZURE-1 primary endpoint: 56%/45% vs 0% delayed treatment; p<0.0001

Mirum adds a near-term FOP launch while brelovitug clears its first pivotal HDV test, strengthening a broader rare-disease growth platform.

Mirum is moving from a commercial rare-disease base into a broader, multi-product platform: it already sells LIVMARLI, CHOLBAM and CTEXLI, while building late-stage programs in HDV, cholestatic liver disease and FOP. The filing materially advances that expansion on two fronts. FDA approval of Atebrioz gives Mirum a second near-term commercial launch, with U.S. availability expected in October; the approval itself was not a surprise because the September 26, 2026 priority-review date was already known, so this is partly confirmation rather than a wholly new event. 〔0〕

The bigger incremental signal is brelovitug’s AZURE-1 result. In a pivotal study, 56% of patients on 300 mg weekly and 45% on 900 mg every four weeks achieved the combined virologic-response and ALT-normalization endpoint, versus 0% for delayed treatment, with p<0.0001 for both comparisons. The direction was partly anticipated from earlier AZURE-1 data, but a positive Phase 3 result across both doses substantially de-risks the program and moves it toward the remaining pivotal AZURE-4 readout and a planned BLA in the first half of 2027.

The filing strengthens the portfolio, but does not finish the HDV story. AZURE-1 is only one of two Phase 3 studies intended for the U.S. registration package, and full results have not yet been presented; the second pivotal study remains the key validation step. The company’s more than $1 billion brelovitug revenue estimate and more than $200 million Atebrioz estimate are management projections, not demonstrated sales. Bottom line: This is a meaningful pipeline-to-commercial step-up: a scheduled FOP approval becomes a launch, while a strong first pivotal HDV result materially improves the case for a second major product. The remaining AZURE-4 result still matters for registration certainty.

What to watch next

AZURE-4 topline results, fourth quarter 2026

Original filing on SEC EDGAR

More Mirum Pharmaceuticals, Inc. news

Mirum wins FOP approval and posts strong AZURE-1 HDV result | MIRM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.